Bruce v. Kilitch Healthcare India, Ltd.

CourtDistrict Court, D. Kansas
DecidedMarch 26, 2025
Docket2:24-cv-02397
StatusUnknown

This text of Bruce v. Kilitch Healthcare India, Ltd. (Bruce v. Kilitch Healthcare India, Ltd.) is published on Counsel Stack Legal Research, covering District Court, D. Kansas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bruce v. Kilitch Healthcare India, Ltd., (D. Kan. 2025).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF KANSAS

SARAH BRUCE,

Plaintiff,

v. Case No. 24-2397-DDC-BGS

KILITCH HEALTHCARE INDIA, LTD., et al..,

Defendants.

MEMORANDUM & ORDER ON MOTION FOR JURISDICTIONAL DISCOVERY NOW BEFORE THE COURT is Plaintiff’s “Motion for Jurisdictional Discovery.” (Doc. 34.) Therein, Plaintiff moves for an Order allowing her counsel to conduct limited jurisdictional discovery regarding Defendants Kilitch Healthcare India, Ltd. (“Kilitch”) and Velocity Pharma, LLC (“Velocity”) in order to “respond fully” to Motions to Dismiss filed by these Defendants.1 Kilitch and Velocity have moved to dismiss the claims against them, alleging a lack of personal jurisdiction. (Docs. 22, 24.) Plaintiff argues that “[g]iven that minimal public information is available as to either Defendant, Plaintiff needs jurisdictional discovery to respond fully to these motions.” (Doc. 34, at 1.) For the reasons set forth herein, Plaintiff’s motion is DENIED. FACTUAL BACKGROUND Plaintiff’s Amended Complaint brings claims for products liability, a violation of the Kansas Consumer Protection Act, and loss of consortium as a result of Defendants’ alleged acts and omissions as to the manufacturing, marketing, advertising, labeling, distribution, and sale of allegedly defective eye drops. (See generally Doc. 5.) She alleges that she purchased “Up&Up” branded eyedrops, which are a Target brand, from a Target store in Kansas City, Kansas in September 2022.

1 Target Corporation (“Target”) is also a Defendant herein. While Target was initially thought to not be involved in this dispute because it did not file a Motion to Dismiss, Plaintiff has indicated she will potentially request discovery from Target relating to Defendants Kilitch and Velocity. According to Plaintiff, contractual agreements between Kilitch and/or Velocity and Target caused the product that injured [her] to be sold at a Target store in Kansas City, Kansas. (Id., at ¶ 26.) Plaintiff alleges that she used the eye drops “consistent with the product’s instructions/directions,” but shortly after doing so, she “began experiencing loss of vision, pain, aches, and discharge in her right eye, as well as headaches.” (Doc. 34, at 2.) She continues that after treatment, she “learned that she had developed a severe corneal ulcer infection, as result of using the

Up&Up eyedrops.” (Id.) She contends she has been subjected to pain and suffering, a loss of vision, scarring and disfigurement of her eye, medical expenses, loss of services, and lost wages. (Id.) According to Plaintiff, the FDA recalled these eyedrops in October 2023 “and warned consumers not to purchase or use them.” (Id.) She alleges that the FDA found “insanitary conditions in the manufacturing facility and positive bacterial test results from environmental sampling of critical drug production areas in the facility.” (Doc. 5, at ¶ 22.) In her Amended Complaint, Plaintiff alleges that this Court has personal jurisdiction “over all Defendants” because each of them[ ] have conducted and do business in the State of Kansas, have induced acts in the State of Kansas, have substantial and continuing contact with the State of Kansas by marketing, promoting, distributing, and selling the Product at issue herein … to consumers in the State of Kansas on a regular and consistent basis. Further, Defendants have minimum contacts with, have purposefully directed their activities toward, and have committed a tort(s) in the State of Kansas such that taking jurisdiction over them would not offend traditional notions of fair play and substantial justice.

(Id., at ¶ 7.) The Motion to Dismiss filed by Kilitch generally argues that Plaintiff’s Complaint fails to establish “how an Indian corporation halfway across the world that has neither conducted business in Kansas nor made a single contact, let alone sufficient minimum contacts, with Kansas is responsible for her alleged injuries.” (Doc. 22-1, at 3-4.) Kilitch continues that “Plaintiff’s jurisdictional allegations are no more than shotgun pleadings directed toward all Defendants without specifying each Defendant’s contacts and actions within Kansas.” (Id.) Velocity’s Motion to Dismiss raises similar issues, arguing that it was improper for Plaintiff to allege the Court’s personal jurisdiction over it “based on [this] vague and boilerplate allegation … .” (Doc. 24, at 7.) Velocity continues that it “did not sell or distribute the product at issue in this case in Kansas,” thus Plaintiff “has no proof of activities within Kansas meeting the standard of

purposeful availment and proof that purposeful availment was causally connected to the alleged injury.” (Id.) In conjunction with their Motions to Dismiss, Defendants Kilitch and Velocity both filed succinct declarations from a corporate officer. The Kilitch declaration was from its Director Divya Mehta, who indicates Kilitch manufactured the eyedrops at issue. (Doc. 22-2, at ¶ 2.) Mehta claims that Kilitch has no business operations in the United States generally or Kansas specifically and did not engage in any business in the United States or Kansas related to these eyedrops. (Id., at ¶¶ 4-5.) That stated, Mehta’s declaration indicates that Kilitch manufactures the eyedrops and then sends the product to Velocity in the United States. (Id. at ¶¶ 8-9.) This declaration is silent as to the relationship between Kilitch and Target as well as Kilitch’s knowledge regarding where the product would be sold. (See generally id.) The Velocity declaration is that of its CEO, Ankur Shah. (Doc. 24-1, at ¶ 2). According to Shah, Velocity is an LLC organized and with its principal place of business in New York. (Id. at ¶ 3).

He admits that Velocity distributed the eyedrops at issue to Target, which were picked up by Target from Velocity’s warehouse in New York and not shipped by Velocity to any location in Kansas. (Id., at ¶ 4.) The declaration is otherwise silent as to Velocity’s relationship with Target as well as Velocity’s knowledge regarding where the product was sold. (See generally id.) ANALYSIS I. Legal Standard. Because federal courts are courts of limited jurisdiction, “there is a presumption against … jurisdiction … .” Penteco Corp. P’ship – 1985A v. Union Gas Sys., Inc., 929 F.2d 1519, 1521 (10th Cir. 1991). In bringing her claims in federal court, “Plaintiff bears the burden of establishing personal jurisdiction over the defendant[s].” Rambo v. American Southern Ins. Co., 839 F.2d 1415, 1417 (10th Cir.1988). See also Wenz v. Memery Crystal, 55 F.3d 1503, 1505 (10th Cir. 1995) (holding, in the

context of affirming a dismissal for lack of personal jurisdiction, that “when the court’s jurisdiction is contested, the plaintiff has the burden of proving jurisdiction exists”) (citations omitted). That stated, a plaintiff’s burden to do so at this stage of the litigation is light. Doe v. National Medical Servs., 974 F.2d 143, 145 (10th Cir.1992) (affirming the District Court’s dismissal for lack of personal jurisdiction). In establishing personal jurisdiction, “[t]he allegations in the complaint must be taken as true to the extent they are uncontroverted by the defendant’s affidavits.” Wenz, 55 F.3d at 1505 (citation omitted). See also Echtinaw v. Lappin, 08-3011-KHV, No. 2009 WL 604131, at *6 (in the context of deciding a motion to dismiss for lack of personal jurisdiction) (citation omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
Bruce v. Kilitch Healthcare India, Ltd., Counsel Stack Legal Research, https://law.counselstack.com/opinion/bruce-v-kilitch-healthcare-india-ltd-ksd-2025.